Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 17:15:61-66.
doi: 10.2147/BTT.S297712. eCollection 2021.

Glomerulonephritis in Two Patients with SpA Treated with TNF-α Blockers and a Review of the Literature

Constantina A Bounia  1 , Eftichia N Theodoropoulou  1 , Stamatic-Nick C Liossis  1   2
Affiliations
Review

Glomerulonephritis in Two Patients with SpA Treated with TNF-α Blockers and a Review of the Literature

Constantina A Bounia et al. Biologics. .

Abstract

Renal failure or acute/chronic kidney damage may present as a clinical manifestation of rheumatic diseases. In addition treatment with DMARDs or biologic drugs may induce nephrotoxicity. In this case-based review, we present two patients with SpA under anti-TNF-α treatment admitted to our hospital because of renal failure and proteinuria. We review previously published yet isolated cases of TNF-α blocker-induced glomerular disease in patients with SpA. Renal manifestations are occasionally seen in patients with ankylosing spondylitis and psoriatic arthritis with IgA nephropathy being the most common of them. Anti-TNF-α agents although reportedly used for the treatment of glomerular nephropathy as a disease manifestation, they have been considered responsible for provoking renal damage in some cases. A diagnostic approach for patients with SpA treated with anti-TNF-α agents presenting with renal manifestations is proposed herein.

Keywords: anti-TNF-alpha agents; glomerular disease; kidney biopsy; proteinuria; spondylarthritides.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
A proposed decision tree on the approach of the patient with SpA and renal involvement.
See this image and copyright information in PMC

References

    1. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha; therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–1406. doi: 10.1093/ndt/gfh832 - DOI - PubMed
    1. Ayaash A, Maan D, Kapetanos A, Bunker M, Wasko MC, Clark B. Significance of crescentic glomeruli in acute kidney injury with rheumatoid arthritis. Case Reports Nephrol Dial. 2019;9:42–48. doi: 10.1159/000500105 - DOI - PMC - PubMed
    1. Premužić V, Padjen I, Cerovec M, Ćorić M, Jelaković B, Anić B. The association of TNF-alpha inhibitors and development of IgA nephropathy in patients with rheumatoid arthritis and diabetes. Case Rep Nephrol. 2020. - PMC - PubMed
    1. Morgane V, Jean-Charles C, Nicolas M, et al. Renal sarcoid-like granulomatosis during anti-TNF therapy. Kidney Int. 2014;86:215. doi: 10.1038/ki.2013.452 - DOI - PubMed
    1. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22:847–861. doi: 10.1016/j.berh.2008.09.008 - DOI - PubMed